Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
No Overlap among Serum GAD65, NMDAR and AQP4 Antibodies in Patients with Neuromyelitis Optica Spectrum Disorders.
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.
Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis.
Nonallergic comorbidities of atopic eczema: an overview of systematic reviews.
Major depression and multiple sclerosis - a case report.
Similar genetics of adult and pediatric MS: Age is just a number.
Does Aquaporin-4-Seronegative Neuromyelitis Optica Exist?
Fluctuations in appraisal over time in the context of stable versus non-stable health.
Longitudinally extensive varicella-zoster virus myelitis in a multiple sclerosis patient.
Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis.
The complex immunology of multiple sclerosis.
Multiple sclerosis: a review of the disease and treatment options.
Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment.
Novel remyelination strategy for multiple sclerosis in the era of oligodendrocytopathy.
NLRP3 Inflammasome and MS/EAE.
Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.
Patient with Neuromyelitis Optica Spectrum Disorder Combined with Sjögren's Syndrome Relapse Free Following Tacrolimus Treatment.
Identifying Modulators of CXC Receptors 3 and 4 with Tailored Selectivity using Multi-Target Docking.
TREM2 regulates microglial cell activation in response to demyelination in vivo.
Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin injection treatments.
VLA4 Gene Polymorphism and Susceptibility to Multiple Sclerosis in Slovaks.
Abnormal adaptation over time of motor network recruitment in multiple sclerosis patients with fatigue.
Central Nervous System Infections With Immunomodulatory Therapies.
Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Change of Th17 Lymphocytes and Treg/Th17 in Typical and Atypical Optic Neuritis.
Pages
« first
‹ previous
…
349
350
351
352
353
354
355
356
357
…
next ›
last »